ClinicalThought
View More
Despite the advance of newer immunotherapies and targeted agents for the treatment of RCC, high-dose IL-2 has an important role in achieving a durable response. Read my thoughts on when to consider it and which patients may benefit the most.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.